Any content you receive is for information purposes only. Always conduct your own research.*Sponsored
Market Crux Just Announced (SXTP) Will Be Topping Our Watchlist
Tomorrow Morning—Monday, February 2, 2026.
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage Will Be Starting Early
Pull Up (SXTP) Before Tomorrow Morning… February 1, 2026 Monday's Headliner | See Why (SXTP) Will Be On Our Radar Early Tomorrow Dear Reader, The global health landscape is shifting as tick-borne illnesses and tropical pathogens move into new territories, increasing demand for targeted medical countermeasures. One small infectious-disease specialist already has an FDA-approved foundation in place—and is now using that same chemistry to pursue a problem with no FDA-approved, purpose-built treatment. 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) is positioning itself to address significant unmet needs in infectious disease management. And that's just one of the reasons (SXTP) will be topping our watchlist tomorrow morning—Monday, February 2, 2026. But keep in mind, (SXTP) has less than 1M shares listed as available to the public, according to Yahoo. When companies have small floats like this, the potential exists for big moves if demand begins to change. And it's already showing on the tape. (SXTP) just made an approximate 360% move in less than 24 hours, from $1.86 on January 21 to $8.62 on January 22. 
As the only company with an FDA-approved tafenoquine product for malaria prevention in nearly two decades, this Washington, D.C.-based company is now studying tafenoquine in chronic babesiosis. Redefining Defense Against Infectious Disease
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) operates as a specialty pharmaceutical firm dedicated to the development and commercialization of new medicines for infectious diseases. Headquartered in the Washington, D.C. biotech hub, the company maintains a strategic proximity to major regulatory bodies like the FDA and NIH. Their primary mission involves identifying "broken" or underserved markets within the infectious disease space where existing treatments are either nonexistent or plagued by significant side effects. 
The company's commercial cornerstone is ARAKODA®, a medicinal profile of tafenoquine approved by the FDA for the prophylaxis of malaria in adults. While malaria remains a global focus, (SXTP) is aggressively expanding its clinical pipeline to include treatments for babesiosis, a tick-borne parasitic infection that is increasingly prevalent in the Northeastern and Midwestern United States. By utilizing its existing intellectual property and deep expertise in synthetic chemistry, (SXTP) aims to provide the first-ever FDA-approved treatment specifically indicated for this "malaria-of-the-north." The Strategic Pivot to Babesiosis
One of the most compelling aspects of the 60 Degrees Pharmaceuticals, Inc. narrative is its targeted approach to babesiosis. This disease, caused by the Babesia parasite, is often transmitted by the same black-legged ticks that carry Lyme disease. Despite its rising incidence, there is currently no FDA-approved treatment specifically indicated for babesiosis. Patients are often treated with "off-label" combinations that may not be fully effective or well-tolerated. The company recently announced groundbreaking findings from a peer-reviewed study at North Carolina State University, which detected Babesia infection in 24 percent of patients presenting with chronic fatigue. This data supports a long-held theory that persistent infection may be a hidden driver of long-term fatigue syndromes. To address this, (SXTP) has launched the B-FR-EE Chronic Babesiosis Study, evaluating a 90-day tafenoquine regimen in patients with chronic babesiosis and severe fatigue. With enrollment underway at sites including the Mount Sinai Icahn School of Medicine, the study is an important step toward generating clinical data that could inform future regulatory discussions for tafenoquine in babesiosis. Commercial Scaling and 2026 Growth Drivers
The transition from a research-heavy organization to a commercial powerhouse is well underway. In December 2025, (SXTP) announced a significant expansion of ARAKODA® sales and marketing for the 2026 calendar year. This move was triggered by a successful six-month pilot program that demonstrated clear demand among prescribers. The expansion strategy is multi-faceted: - Sales Force Doubling: The company is doubling its number of sales representatives to increase face-to-face engagement with healthcare providers.
- GoodRx Partnership: A new partnership with GoodRx aims to improve patient access and affordability, removing common hurdles at the pharmacy counter.
- Telehealth Integration: Through a partnership with Runway Health, international travelers can now access physician-led consultations and have ARAKODA® delivered directly to their homes.
These initiatives are designed to accelerate the growth of ARAKODA®, which saw a 223% increase in revenue during Q3 2025 compared to the same period the previous year. 
Diversification and Scientific Innovation
Beyond prescription medicine, (SXTP) is exploring high-margin, non-prescription opportunities. In late January 2026, the company exercised its license option with Florida State University for the large-scale purification of Castanospermine. Extracted from Australian Chestnut seeds, this compound has shown potential in modulating carbohydrate metabolism and immunomodulation. By targeting the non-Rx botanical market, (SXTP) can leverage its scientific expertise to generate revenue through pathways that do not require the decade-long timelines typically associated with new molecular entities. This diversification provides a strategic buffer while the company continues its high-stakes clinical trials in viral and fungal diseases. Corporate Structure and Financial Health
To better position itself within the capital markets and ensure compliance with exchange requirements, (SXTP) implemented a 1-for-4 reverse split effective January 20, 2026. This action consolidated the share structure, reducing the total outstanding common stock to approximately 1.29M shares. Product revenue grew sharply year over year in Q3 2025, supporting the view that the company is making progress as it expands commercial execution.The company's lean management team, led by CEO Geoffrey Dow, Ph.D., brings over 20 years of experience in tropical disease product development, much of it gained through leadership roles at the Walter Reed Army Institute of Research. The Path Ahead: 12-18 Month Outlook
Over the next 12–18 months, several company-identified milestones are set to stay in focus, including continued enrollment in the B-FR-EE study and the planned 2026 expansion of ARAKODA® commercial efforts. The company has also outlined additional digital outreach initiatives and announced a telehealth channel through Runway Health, broadening how eligible patients may access consultations and, if prescribed, medication ahead of travel. The company's presence in the Washington, D.C. biotech region provides a strategic advantage, allowing for close collaboration with public health experts as they navigate the regulatory hurdles for new babesiosis indications. As the medical community increasingly recognizes the link between tick-borne pathogens and chronic illness, (SXTP) stands ready with a validated solution. 7 Reasons Why (SXTP) Will Be Topping Our Watchlist Tomorrow Morning—Monday, February 2, 2026
1. Small Float: With less than 1M shares listed as available to the public, (SXTP)'s small float could have the potential for big moves if demand befings to change. 2. Recent Momentum: (SXTP) has shown significant short-term movement— from $1.86 on Jan 21 to $8.62 on Jan 22, an approx. 360% swing in under 24 hours. 3. Revenue Growth: (SXTP) reported a 223% increase in product revenue in Q3 2025, demonstrating that its commercial strategy for ARAKODA® is gaining significant traction. 4. Aggressive Expansion: (SXTP)'s plan to double its sales force in 2026 reflects management's push to broaden awareness and adoption of ARAKODA® among appropriate prescribers. 5. High-Value Partnerships: (SXTP)'s collaborations with GoodRx and Runway Health add newer access channels—supporting patient affordability at the pharmacy and telehealth-enabled consultations for eligible travelers. 6. Unmet Medical Need: There is currently no FDA-approved treatment for babesiosis, positioning (SXTP) to potentially be the first to market in a high-value addressable category. 7. Potential Near-Term Clinical Catalysts: Mount Sinai is now open for enrollment in (SXTP)'s B-FR-EE chronic babesiosis study, supporting the potential for news flow as the trial advances in 2026. Pull Up (SXTP) Before Tomorrow Morning…
Taken together, (SXTP) checks several boxes that tend to keep a ticker in active circulation: a relatively small public float, a recent reminder of how quickly attention can concentrate (the move from $1.86 on Jan 21 to $8.62 on Jan 22, about +360% in under 24 hours), and a commercial story that's showing traction (the company reported a 223% year-over-year increase in Q3 2025 product revenue tied to ARAKODA®). And it's not just backward-looking. (SXTP) has outlined 2026 commercial expansion, including plans to double its sales force, alongside access-focused channels like GoodRx and a telehealth pathway with Runway Health. On the clinical side, Mount Sinai is open for enrollment in the B-FREE chronic babesiosis study—an area where there is no FDA-approved, specifically indicated treatment today. We will have all eyes on (SXTP) tomorrow morning. Take a look at (SXTP) before you call it a night. Also, keep a lookout for my morning update, it could be coming bright and early. Have a good night. Sincerely, Gary Silver
Managing Editor,
Market Crux
| 
0 التعليقات:
إرسال تعليق